who draws this board
About CJC-1295 Telehealth
An independent editorial project that draws the CJC-1295 literature out as plain flowcharts. No clinic, no products, no medical advice — a teaching board for what the studies actually show.
What this site is
CJC-1295 Telehealth is an independent editorial project that publishes summaries of the peer-reviewed research literature on CJC-1295. We are not a clinic. We do not employ clinicians and we do not provide medical advice. We do not manufacture, sell, or distribute any product. Our work is editorial commentary on publicly available science.
The whole site is built as a whiteboard. CJC-1295's literature is a set of flows — a mechanism cascade from receptor to GH to IGF-1, a structural fork between the long-acting DAC form and the short-acting no-DAC Modified GRF (1-29), and a detection pipeline that runs from a seized sample through mass spectrometry to identification — and a flowchart is the most honest way to draw each of them. Where the record is solid, we draw the arrow and cite the number. Where it stops, we say so on the board rather than off it.
What "telehealth" means here
The word "telehealth" in this domain is editorial framing, not a description of a service. It names the explanatory, walk-you-through-it register of someone sketching a pathway on a whiteboard — clear, patient, step by step. It is not a tele-consultation, not an appointment booking, and not a storefront. No prescriptions are written here, no products are dispensed, and no consultation is offered or implied.
The distinction matters because CJC-1295 is an unapproved research chemical with a short human evidence base, and the internet around it is crowded with marketing that blurs exactly the lines we try to keep sharp: DAC versus no-DAC, mechanism versus outcome, what a study measured versus what a vendor claims. This project's only job is to keep those lines visible.
How we handle the evidence
Every quantitative claim on this site — every dose, half-life, fold-change, and duration — maps to a numbered citation in the reference list, drawn from PubMed-indexed studies, the WADA International Standard, and the FDA's compounding-committee record. We lead with what was measured and attribute it to the study that measured it. We describe doses as administered to a species by a route; we never recommend a human dose, because no approved dose exists. When the literature is silent or the program was discontinued, that gap is part of the picture, drawn plainly. The site is a digest of the published record, kept current as that record grows.